Press release
Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024
HOLON, Israel, March 6, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in
About this update from Compugen Ltd.
[{"type":"text","content":"HOLON, Israel, March 6, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will present data from its differentiated immuno-oncology preclinical and clinical pipeline, in two poster presentations at the American Association for Cancer Research (AACR) annual meeting on April 5-11, 2024, in San Diego, California.\n\n\"It is exciting that the progress we have made to potentially address immunotherapy resistance from diverse angles will be reflected at AACR this year,\" said Anat Cohen-Dayag, Ph.D., President, and CEO of Compugen. \"While PVRIG and TIGIT are novel targets discovered with our computational discovery platform, more recently, we have also discovered a unique and differentiated way to target a known biological pathway, the IL-18 binding protein pathway.\"\nEran Ophir, Ph.D., Chief Scientific Officer at Compugen, added, \"At ACCR we will present data supporting the unique biology of PVRIG suggesting its role in sensitizing tumors to other immune checkpoints TIGIT and PD-(L)1. In addition, in a second presentation we will present data supporting the therapeutic potential of our high affinity, potential first-in-class, anti-IL-18 binding protein antibody, COM503, showing its activity is localized to the tumor microenvironment with the potential advantage of a wider therapeutic window than systemically delivered cytokines.\"\nPoster details:Session Date and Time: Tuesday, April 9, 2024, 9:00 AM - 12:30 PM PSTSession Category: ImmunologySession Title: Immune Modulation with CytokinesPoster Title: Unleashing natural IL-18 activity using an anti-IL-18BP blocker antibody induces potent immune stimulation and anti-tumor effectsPublished Abstract Number: 4072\nSession Date and Time: Wednesday, April 10, 2024, 9:00 AM - 12:30 PM PSTSession Category: Clinical ResearchSession Title: Immune Checkpoint Inhibitor TherapyPoster Title: PVRIG is uniquely expressed in tumor dendritic cells-rich niches on stem-like memory T cells and its blockade may induce immune infiltration and activation in non-inflamed tumorPublished Abstract Number: 7533\nThe abstracts are available on Compugen's website at www.cgen.com. The data will be published in the online Proceedings supplement to the AACR journal Cancer Research pr...